Other Information
+Added: Exhibit Number
Description of Exhibit
−Removed: OptimizeRx 2021 Equity Incentive Plan.
−Removed: Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on August 25, 2021.
−Removed: Form of Stock Option Award for grants under the OptimizeRx Corporation 2021 Equity Incentive Plan.
−Removed: Incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed on August 25, 2021.
−Removed: Form of Performance Stock Option Award for grants under the OptimizeRx Corporation 2021 Equity Incentive Plan.
−Removed: Incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K filed on August 25, 2021.
−Removed: Form of Restricted Stock Unit Award for grants under the OptimizeRx Corporation 2021 Equity Incentive Plan.
−Removed: Incorporated by reference to Exhibit 10.4 to the Company’s Current Report on Form 8-K filed on August 25, 2021.
−Removed: Form of Performance Restricted Stock Unit Award for grants under the OptimizeRx Corporation 2021.
−Removed: Incorporated by reference to Exhibit 10.5 to the Company’s Current Report on Form 8-K filed on August 25, 2021.
−Removed: Offer Letter by and between the Company and Edward Stelmakh.
−Removed: Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on September 30, 2021.
+Added: OptimizeRx Corporation 2022 Cash Bonus Plan.
+Added: Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on March 4, 2022.
+Added: Amendment to Employment Agreement by and between the Company and Stephen Silvestro dated February 28, 2022.
+Added: Incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed on March 4, 2022.
+Added: Amendment to Employment Agreement by and between the Company and Marion Odence-Ford dated February 28, 2022.
+Added: Incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K filed on March 4, 2022.
Certification of Chief Executive Officer pursuant to 18 U.S.C.
10 unchanged sentences
Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
−Removed: * Exhibits have been omitted to
−Removed: Item 601(a)(5) of Regulation S-K.
−Removed: The Company agrees to furnish supplementally a copy of any omitted exhibit to the SEC upon request.
** Provided herewith
−Removed: accordance with the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed
−Removed: on its behalf by the undersigned, thereunto duly authorized.
+Added: Pursuant to the requirements of the Securities Exchange Act of 1934,
+Added: the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
OptimizeRx Corporation
−Removed: November 9, 2021
−Removed: Chief Executive Officer and
+Added: /s/ William J.
+Added: Chief Executive Officer
(principal executive officer)
OptimizeRx Corporation
−Removed: November 9, 2021
+Added: /s/ Edward Stelmakh
Edward Stelmakh
−Removed: Chief Financial Officer,
−Removed: Principal Financial Officer and
−Removed: Principal Accounting Officer
+Added: Chief Financial Officer and
+Added: Chief Operations Officer
+Added: (principal financial and accounting officer)
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.